When treating a patient with multiple myeloma with bortezomib, how do you decide between subcutaneous vs intravenous dosing?  

Subq has been shown to have lower risk of neuropathy. Is there any reason to use weekly IV still?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice